Complement-mediated ischemia-reperfusion injury: Lessons learned from animal and clinical studies

Annals of Surgery

Volumn 249, Issue 6, 2009, Pages 889-899

  Diepenhorst, Gwendolyn M P ^a,b   Van Gulik, Thomas M ^a,b   Hack, C Erik ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; COBROTOXIN; COMPLEMENT; COMPLEMENT C5A RECEPTOR ANTAGONIST; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C7; COMPLEMENT COMPONENT C8; COMPLEMENT COMPONENT C9; COMPLEMENT INHIBITOR; COMPLEMENT RECEPTOR RELATED GENE Y PROTEIN; DECAY ACCELERATING FACTOR; EPITOPE; LECTIN; MANNOSE BINDING LECTIN; MONOCLONAL ANTIBODY; MYOSIN HEAVY CHAIN; NONMUSCLE MYOSIN HEAVY CHAIN TYPE IIA; NONMUSCLE MYOSIN HEAVY CHAIN TYPE IIC; PEXELIZUMAB; PHOSPHOLIPID; PHOSPHORYLCHOLINE; SOLUBLE COMPLEMENT RECEPTOR 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE KIDNEY FAILURE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT LECTIN PATHWAY; COMPLEMENT SYSTEM; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HINDLIMB; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE INJURY; INTESTINE ISCHEMIA; ISCHEMIA; KIDNEY INJURY; KIDNEY ISCHEMIA; KNOCKOUT MOUSE; LIMB ISCHEMIA; LIVER INJURY; NONHUMAN; PRIORITY JOURNAL; REPERFUSION; REPERFUSION INJURY; REVIEW; TISSUE LEVEL; ANIMAL; DISEASE MODEL; KIDNEY DISEASE; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; HUMANS; KIDNEY DISEASES; MICE; RATS; REPERFUSION INJURY;

EID: 67649197049     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181a38f45     Document Type: Review

References (137)

1. Cotran RS. Ischemic and hypoxic injury. In: Cotran RS, ed. Robbins Pathologic Basis of Disease. St. Louis, MO: WB Saunders Company; 1999:7-12.
2. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121-1135.
3. Becker LB. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res. 2004;61:461-470.
4. Cannon RO III. Mechanisms, management and future directions for reperfusion injury after acute myocardial infarction. Nat Clin Pract Cardiovasc Med. 2005;2:88-94.
5. Cerqueira NF, Hussni CA, Yoshida WB. Pathophysiology of mesenteric ischemia/reperfusion: a review. Acta Cir Bras. 2005;20:336-343.
6. Li C, Jackson RM. Reactive species mechanisms of cellular hypoxiareoxygenation injury. Am J Physiol Cell Physiol. 2002;282:C227-C241.
7. Watts JA, Kline JA. Bench to bedside: the role of mitochondrial medicine in the pathogenesis and treatment of cellular injury. Acad Emerg Med. 2003; 10:985-997.
8. Cuzzocrea S, Di PR, Mazzon E, et al. WY 14643, a potent exogenous PPAR-alpha ligand, reduces intestinal injury associated with splanchnic artery occlusion shock. Shock. 2004;22:340-346.
9. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53:31-47.
10. Mbachu EM, Klein LV, Rubin BB, et al. A monoclonal antibody against cytokine-induced neutrophil chemoattractant attenuates injury in the small intestine in a model of ruptured abdominal aortic aneurysm. J Vasc Surg. 2004;39:1104-1111.
11. Sorkine P, Setton A, Halpern P, et al. Soluble tumor necrosis factor receptors reduce bowel ischemia-induced lung permeability and neutrophil sequestration. Crit Care Med. 1995;23:1377-1381.
12. Arndt H, Kubes P, Granger DN. Involvement of neutrophils in ischemiareperfusion injury in the small intestine. Klin Wochenschr. 1991;69:1056-1060.
13. Carmody IC, Meng L, Shen XD, et al. P-selectin knockout mice have improved outcomes with both warm ischemia and small bowel transplantation. Transplant Proc. 2004;36:263-264.
14. Kurtel H, Granger DN, Tso P, et al. Vulnerability of intestinal interstitial fluid to oxidant stress. Am J Physiol. 1992;263:G573-G578.
15. Schmeling DJ, Caty MG, Oldham KT, et al. Evidence for neutrophil-related acute lung injury after intestinal ischemia-reperfusion. Surgery. 1989;106: 195-201.
16. Semenza GL. Cellular and molecular dissection of reperfusion injury: ROS within and without. Circ Res. 2000;86:117-118.
17. Sisley AC, Desai T, Harig JM, et al. Neutrophil depletion attenuates human intestinal reperfusion injury. J Surg Res. 1994;57:192-196.
18. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res. 2004;61:481-497.
19. Zimmerman GA, McIntyre TM, Prescott SM, et al. Brief review: molecular mechanisms of neutrophil binding to endothelium involving platelet-activating factor and cytokines. J Lipid Mediat. 1990;2(suppl):S31-S43.
20. Briaud SA, Ding ZM, Michael LH, et al. Leukocyte trafficking and myocardial reperfusion injury in ICAM-1/P-selectin-knockout mice. Am J Physiol Heart Circ Physiol. 2001;280:H60-H67.
21. Simpson R, Alon R, Kobzik L, et al. Neutrophil and nonneutrophilmediated injury in intestinal ischemia-reperfusion. Ann Surg. 1993;218: 444-453.
22. Ito H. No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med. 2006;3:499-506.
23. Mastellos D, Morikis D, Isaacs SN, et al. Complement: structure, functions, evolution, and viral molecular mimicry. Immunol Res. 2003;27:367-386.
24. Gadjeva M, Takahashi K, Thiel S. Mannan-binding lectin-a soluble pattern recognition molecule. Mol Immunol. 2004;41:113-121.
25. Roos A, Bouwman LH, Munoz J, et al. Functional characterization of the lectin pathway of complement in human serum. Mol Immunol. 2003;39: 655-668.
26. Tsutsumi A, Takahashi R, Sumida T. Mannose binding lectin: genetics and autoimmune disease. Autoimmun Rev. 2005;4:364-372.
27. Turner MW. The role of mannose-binding lectin in health and disease. Mol Immunol. 2003;40:423-429.
28. Worthley DL, Bardy PG, Mullighan CG. Mannose-binding lectin: biology and clinical implications. Intern Med J. 2005;35:548-555.
29. Vorup-Jensen T, Petersen SV, Hansen AG, et al. Distinct pathways of mannan-binding lectin (MBL)- and C1-complex autoactivation revealed by reconstitution of MBL with recombinant MBL-associated serine protease-2. J Immunol. 2000;165:2093-2100.
30. Hajela K, Kojima M, Ambrus G, et al. The biological functions of MBLassociated serine proteases (MASPs). Immunobiology. 2002;205:467-475.
31. Hill JH, Ward PA. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med. 1971;133:885-900.
32. Atkinson C, Song H, Lu B, et al. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest. 2005;115:2444-2453.
33. Eror AT, Stojadinovic A, Starnes BW, et al. Antiinflammatory effects of soluble complement receptor type 1 promote rapid recovery of ischemia/reperfusion injury in rat small intestine. Clin Immunol. 1999;90:266-275.
34. Hill J, Lindsay TF, Ortiz F, et al. Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemiareperfusion in the rat. J Immunol. 1992;149:1723-1728.
35. Karpel-Massler G, Fleming SD, Kirschfink M, et al. Human C1 esterase inhibitor attenuates murine mesenteric ischemia/reperfusion induced local organ injury. J Surg Res. 2003;115:247-256.
36. Wada K, Montalto MC, Stahl GL. Inhibition of complement C5 reduces local and remote organ injury after intestinal ischemia/reperfusion in the rat. Gastroenterology. 2001;120:126-133.
37. Williams JP, Pechet TT, Weiser MR, et al. Intestinal reperfusion injury is mediated by IgM and complement. J Appl Physiol. 1999;86:938-942.
38. Padilla ND, van Vliet AK, Schoots IG, et al. C-reactive protein and natural IgM antibodies are activators of complement in a rat model of intestinal ischemia and reperfusion. Surgery. 2007;142:722-733.
39. Rehrig S, Fleming SD, Anderson J, et al. Complement inhibitor, complement receptor 1-related gene/protein y-Ig attenuates intestinal damage after the onset of mesenteric ischemia/reperfusion injury in mice. J Immunol. 2001;167:5921-5927.
40. Maroko PR, Carpenter CB, Chiariello M, et al. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J Clin Invest. 1978;61:661-670.
41. Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation. 1995;91:393-402.
42. Buerke M, Schwertz H, Seitz W, et al. Novel small molecule inhibitor of C1s exerts cardioprotective effects in ischemia-reperfusion injury in rabbits. J Immunol. 2001;167:5375-5380.
43. Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 1990;249:146-151.
44. Weisman HF, Bartow T, Leppo MK, et al. Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium. Trans Assoc Am Physicians. 1990;103:64-72.
45. Vakeva AP, Agah A, Rollins SA, et al. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation. 1998;97:2259-2267.
46. Thurman JM, Royer PA, Ljubanovic D, et al. Treatment with an inhibitory monoclonal antibody to mouse factor B protects mice from induction of apoptosis and renal ischemia/reperfusion injury. J Am Soc Nephrol. 2006; 17:707-715.
47. de Vries B, Matthijsen RA, Wolfs TG, et al. Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: inhibition of late apoptosis and inflammation. Transplantation. 2003;75:375-382.
48. de Vries B, Kohl J, Leclercq WK, et al. Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J Immunol. 2003;170:3883-3889.
49. Zhou W, Farrar CA, Abe K, et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest. 2000;105:1363-1371.
50. Jaeschke H, Farhood A, Bautista AP, et al. Complement activates Kupffer cells and neutrophils during reperfusion after hepatic ischemia. Am J Physiol. 1993;264:G801-G809.
51. Arumugam TV, Woodruff TM, Stocks SZ, et al. Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats. J Hepatol. 2004;40:934-941.
52. Heijnen BH, Straatsburg IH, Padilla ND, et al. Inhibition of classical complement activation attenuates liver ischaemia and reperfusion injury in a rat model. Clin Exp Immunol. 2006;143:15-23.
53. Lehmann TG, Heger M, Munch S, et al. In vivo microscopy reveals that complement inhibition by C1-esterase inhibitor reduces ischemia/reperfusion injury in the liver. Transpl Int. 2000;13(suppl 1):S547-S550.
54. Montalvo-Jave EE, Escalante-Tattersfield T, Ortega-Salgado JA, et al. Factors in the pathophysiology of the liver ischemia-reperfusion injury. J Surg Res. 2008;147:153-159.
55. Qin X, Gao B. The complement system in liver diseases. Cell Mol Immunol. 2006;3:333-340.
56. Austen WG Jr, Kobzik L, Carroll MC, et al. The role of complement and natural antibody in intestinal ischemia-reperfusion injury. Int J Immunopathol Pharmacol. 2003;16:1-8.
57. Weiser MR, Williams JP, Moore FD Jr, et al. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med. 1996;183:2343-2348.
58. Fleming SD, Shea-Donohue T, Guthridge JM, et al. Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J Immunol. 2002;169:2126-2133.
59. Fleming SD, Egan RP, Chai C, et al. Anti-phospholipid antibodies restore mesenteric ischemia/reperfusion-induced injury in complement receptor 2/complement receptor 1-deficient mice. J Immunol. 2004;173:7055-7061.
60. Reid RR, Woodcock S, Shimabukuro-Vornhagen A, et al. Functional activity of natural antibody is altered in Cr2-deficient mice. J Immunol. 2002; 169:5433-5440.
61. Hart ML, Ceonzo KA, Shaffer LA, et al. Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q. J Immunol. 2005;174:6373-6380.
62. Weeks C, Moratz C, Zacharia A, et al. Decay-accelerating factor attenuates remote ischemia-reperfusion-initiated organ damage. Clin Immunol. 2007; 124:311-327.
63. Kyriakides C, Austen W Jr, Wang Y, et al. Skeletal muscle reperfusion injury is mediated by neutrophils and the complement membrane attack complex. Am J Physiol. 1999;277:C1263-C1268.
64. Nossuli TO, Lakshminarayanan V, Baumgarten G, et al. A chronic mouse model of myocardial ischemia-reperfusion: essential in cytokine studies. Am J Physiol Heart Circ Physiol. 2000;278:H1049-H1055.
65. Zhang M, Michael LH, Grosjean SA, et al. The role of natural IgM in myocardial ischemia-reperfusion injury. J Mol Cell Cardiol. 2006;41:62-67.
66. Michael LH, Entman ML, Hartley CJ, et al. Myocardial ischemia and reperfusion: a murine model. Am J Physiol. 1995;269:H2147-H2154.
67. Walsh MC, Bourcier T, Takahashi K, et al. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol. 2005;175:541-546.
68. Burne-Taney MJ, Ascon DB, Daniels F, et al. B cell deficiency confers protection from renal ischemia reperfusion injury. J Immunol. 2003;171: 3210-3215.
69. Moller-Kristensen M, Wang W, Ruseva M, et al. Mannan-binding lectin recognizes structures on ischaemic reperfused mouse kidneys and is implicated in tissue injury. Scand J Immunol. 2005;61:426-434.
70. Thurman JM, Ljubanovic D, Edelstein CL, et al. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol. 2003;170:1517-1523.
71. Park P, Haas M, Cunningham PN, et al. Injury in renal ischemia-reperfusion is independent from immunoglobulins and T lymphocytes. Am J Physiol Renal Physiol. 2002;282:F352-F357.
72. Zhang M, Austen WG Jr, Chiu I, et al. Identification of a specific selfreactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proc Natl Acad Sci USA. 2004;101:3886-3891.
73. Zhang M, Alicot EM, Chiu I, et al. Identification of the target self-antigens in reperfusion injury. J Exp Med. 2006;203:141-152.
74. Zhang M, Alicot EM, Carroll MC. Human natural IgM can induce ischemia/reperfusion injury in a murine intestinal model. Mol Immunol. 2008;45: 4036-4039.
75. Fleming SD, Monestier M, Tsokos GC. Accelerated ischemia/ reperfusioninduced injury in autoimmunity-prone mice. J Immunol. 2004;173:4230-4235.
76. Chan RK, Verna N, Afnan J, et al. Attenuation of skeletal muscle reperfusion injury with intravenous 12 amino acid peptides that bind to pathogenic Ig M. Surgery. 2006;139:236-243.
77. Chan RK, Ding G, Verna N, et al. IgM binding to injured tissue precedes complement activation during skeletal muscle ischemia-reperfusion. J Surg Res. 2004;122:29-35.
78. Griselli M, Herbert J, Hutchinson WL, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 1999;190:1733-1740.
79. Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006;440:1217-1221.
80. Collard CD, Vakeva A, Morrissey MA, et al. Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol. 2000;156:1549-1556.
81. Jordan JE, Montalto MC, Stahl GL. Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation. 2001;104: 1413-1418.
82. de Zwaan C, Kleine AH, Diris JH, et al. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J. 2002;23:1670-1677.
83. Fattouch K, Bianco G, Speziale G, et al. Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reperfusion: a randomized double-blind study. Eur J Cardiothorac Surg. 2007;32:326-332.
84. Thielmann M, Marggraf G, Neuhauser M, et al. Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction. Eur J Cardiothorac Surg. 2006;30:285-293.
85. Lazar HL, Bokesch PM, van LF, et al. Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation. 2004;110:II274-II279.
86. Carrier M, Menasche P, Levy JH, et al. Inhibition of complement activation by Pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2006;131:352-356.
87. Mahaffey KW, Van de WF, Shernan SK, et al. Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview. Am Heart J. 2006;152: 291-296.
88. Smith PK, Carrier M, Chen JC, et al. Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time. Ann Thorac Surg. 2006;82:781-788.
89. Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the complement inhibition in myocardial infarction treated with Angioplasty (COMMA) trial. Circulation. 2003;108:1184-1190.
90. Mahaffey KW, Granger CB, Nicolau JC, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation. 2003;108:1176-1183.
91. Armstrong PW, Granger CB. Pexelizumab and the APEX AMI trial. JAMA. 2007;297:1881-1882.
92. Verrier ED, Shernan SK, Taylor KM, et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA. 2004;291:2319-2327.
93. Lagrand WK, Niessen HW, Wolbink GJ, et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation. 1997;95:97-103.
94. Nijmeijer R, Lagrand WK, Lubbers YT, et al. C-reactive protein activates complement in infarcted human myocardium. Am J Pathol. 2003;163:269-275.
95. Krijnen PA, Ciurana C, Cramer T, et al. IgM colocalises with complement and C reactive protein in infarcted human myocardium. J Clin Pathol. 2005;58:382-388.
96. Straatsburg IH, Boermeester MA, Wolbink GJ, et al. Complement activation induced by ischemia-reperfusion in humans: a study in patients undergoing partial hepatectomy. J Hepatol. 2000;32:783-791.
97. Cavusoglu E, Eng C, Chopra V, et al. Usefulness of the serum complement component C4 as a predictor of stroke in patients with known or suspected coronary artery disease referred for coronary angiography. Am J Cardiol. 2007;100:164-168.
98. Engstrom G, Hedblad B, Janzon L, et al. Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study. Eur J Cardiovasc Prev Rehabil. 2007;14:392-397.
99. Pedersen ED, Waje-Andreassen U, Vedeler CA, et al. Systemic complement activation following human acute ischaemic stroke. Clin Exp Immunol. 2004;137:117-122.
100. Norwood MG, Sayers RD, Roscher S, et al. Consumption of mannanbinding lectin during abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg. 2006;31:239-243.
101. Fiane AE, Videm V, Lingaas PS, et al. Mechanism of complement activation and its role in the inflammatory response after thoracoabdominal aortic aneurysm repair. Circulation. 2003;108:849-856.
102. Fiane AE, Ueland T, Simonsen S, et al. Low mannose-binding lectin and increased complement activation correlate to allograft vasculopathy, ischaemia, and rejection after human heart transplantation. Eur Heart J. 2005; 26:1660-1665.
103. de Vries B, Walter SJ, Peutz-Kootstra CJ, et al. The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury. Am J Pathol. 2004;165:1677-1688.
104. Garred P, Larsen F, Seyfarth J, et al. Mannose-binding lectin and its genetic variants. Genes Immun. 2006;7:85-94.
105. Madsen HO, Satz ML, Hogh B, et al. Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. J Immunol. 1998;161:3169-3175.
106. Kilpatrick DC. Mannan-binding lectin: clinical significance and applications. Biochim Biophys Acta. 2002;1572:401-413.
107. Cedzynski M, Szemraj J, Swierzko AS, et al. Mannan-binding lectin insufficiency in children with recurrent infections of the respiratory system. Clin Exp Immunol. 2004;136:304-311.
108. Summerfield JA, Sumiya M, Levin M, et al. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. BMJ. 1997;314:1229-1232.
109. Zhang D, Zheng H, Zhou Y, et al. TLR and MBL gene polymorphisms in severe acute pancreatitis. Mol Diagn Ther. 2008;12:45-50.
110. Van Till JW, Boermeester MA, Modderman PW, et al. Variable mannosebinding lectin expression during postoperative acute-phase response. Surg Infect (Larchmt). 2006;7:443-452.
111. Bouwman LH, Roep BO, Roos A. Mannose-binding lectin: clinical implications for infection, transplantation, and autoimmunity. Hum Immunol. 2006;67:247-256.
112. Gordon AC, Waheed U, Hansen TK, et al. Mannose-binding lectin polymorphisms in severe sepsis: relationship to levels, incidence, and outcome. Shock. 2006;25:88-93.
113. Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity. 2007;40:560-566.
114. Falkeis C, Mark W, Sergi C, et al. Kidney transplantation in patients suffering from hereditary complete complement C4 deficiency. Transpl Int. 2007;20:1044-1049.
115. Arnold JN, Wormald MR, Suter DM, et al. Human serum IgM glycosylation: identification of glycoforms that can bind to mannan-binding lectin. J Biol Chem. 2005;280:29080-29087.
116. Nevens JR, Mallia AK, Wendt MW, et al. Affinity chromatographic purification of immunoglobulin M antibodies utilizing immobilized mannan binding protein. J Chromatogr. 1992;597:247-256.
117. Koppel R, Solomon B. IgM detection via selective recognition by mannosebinding protein. J Biochem Biophys Methods. 2001;49:641-647.
118. Suankratay C, Zhang Y, Jones D, et al. Enhancement of lectin pathway haemolysis by immunoglobulins. Clin Exp Immunol. 1999;117:435-441.
119. Arora M, Munoz E, Tenner AJ. Identification of a site on mannan-binding lectin critical for enhancement of phagocytosis. J Biol Chem. 2001;276: 43087-43094.
120. Roos A, Bouwman LH, van Gijlswijk-Janssen DJ, et al. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol. 2001;167:2861-2868.
121. Roos A, Garred P, Wildenberg ME, et al. Antibody-mediated activation of the classical pathway of complement may compensate for mannose-binding lectin deficiency. Eur J Immunol. 2004;34:2589-2598.
122. Zhang M, Takahashi K, Alicot EM, et al. Activation of the lectin pathway by natural IgM in a model of ischemia/reperfusion injury. J Immunol. 2006;177:4727-4734.
123. Dirksen MT, Laarman GJ, Simoons ML, et al. Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies. Cardiovasc Res. 2007;74:343-355.
124. Ku NO, Mortensen RF. Cloning and tissue-specific expression of the gene for mouse C-reactive protein. Biochem J. 1993;295(pt 2):379-386.
125. Whitehead AS, Zahedi K, Rits M, et al. Mouse C-reactive protein. Generation of cDNA clones, structural analysis, and induction of mRNA during inflammation. Biochem J. 1990;266:283-290.
126. Nunomura W, Takakuwa Y, Higashi T. Changes in serum concentration and mRNA level of rat C-reactive protein. Biochim Biophys Acta. 1994;1227: 74-78.
127. de Waal RM, Bogman MJ, Cornelissen IM, et al. Expression of donor class I major histocompatibility antigens on the vascular endothelium of mouse skin allografts. Transplantation. 1986;42:178-183.
128. Tanaka S, Suzuki T, Nishioka K. Assay of classical and alternative pathway activities of murine complement using antibody-sensitized rabbit erythrocytes. J Immunol Methods. 1986;86:161-170.
129. Suresh MV, Singh SK, Ferguson DA Jr, et al. Role of the property of C-reactive protein to activate the classical pathway of complement in protecting mice from pneumococcal infection. J Immunol. 2006;176:4369-4374.
130. Volanakis JE, Kaplan MH. Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. J Immunol. 1974;113:9-17.
131. Caliezi C, Wuillemin WA, Zeerleder S, et al. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev. 2000;52:91-112.
132. Bianchino AC, Poon PH, Schumaker VN. A mechanism for the spontaneous activation of the first component of complement, C1, and its regulation by C1-inhibitor. J Immunol. 1988;141:3930-3936.
133. Gulati S, Sastry K, Jensenius JC, et al. Regulation of the mannan-binding lectin pathway of complement on Neisseria gonorrhoeae by C1-inhibitor and alpha 2-macroglobulin. J Immunol. 2002;168:4078-4086.
134. Fu J, Lin G, Wu Z, et al. Anti-apoptotic role for C1 inhibitor in ischemia/reperfusion-induced myocardial cell injury. Biochem Biophys Res Commun. 2006;349:504-512.
135. Lien YH, Lai LW, Silva AL. Pathogenesis of renal ischemia/reperfusion injury: lessons from knockout mice. Life Sci. 2003;74:543-552.
136. Thrane AS, Skehan JD, Thrane PS. A novel interpretation of immune redundancy and duality in reperfusion injury with important implications for intervention in ischaemic disease. Med Hypotheses. 2007;68:1363-1370.
137. Thibault H, Piot C, Staat P, et al. Long-term benefit of postconditioning. Circulation. 2008;117:1037-1044.